kneat.com (TSE:KSI) Stock Rating Upgraded by Cibc World Mkts

Cibc World Mkts upgraded shares of kneat.com (TSE:KSI) to a strong-buy rating in a research report report published on Tuesday morning, Zacks.com reports.

Several other research firms also recently weighed in on KSI. Ventum Cap Mkts upgraded kneat.com to a “strong-buy” rating in a report on Wednesday, August 7th. CIBC set a C$6.00 price objective on kneat.com and gave the company an “outperform” rating in a research note on Tuesday.

kneat.com Stock Performance

KSI stock opened at C$4.70 on Tuesday. The stock’s fifty day moving average price is C$4.76 and its 200-day moving average price is C$4.44. The company has a market cap of C$404.20 million, a P/E ratio of -29.38, a price-to-earnings-growth ratio of 597.67 and a beta of 1.08. kneat.com has a 1 year low of C$2.68 and a 1 year high of C$5.17. The company has a debt-to-equity ratio of 95.14, a current ratio of 1.47 and a quick ratio of 1.50.

kneat.com (TSE:KSI) last posted its quarterly earnings results on Tuesday, August 6th. The company reported C($0.04) EPS for the quarter, hitting analysts’ consensus estimates of C($0.04). kneat.com had a negative return on equity of 51.13% and a negative net margin of 31.19%. The company had revenue of C$11.68 million for the quarter, compared to analysts’ expectations of C$11.45 million. On average, equities analysts forecast that kneat.com will post -0.12 earnings per share for the current year.

kneat.com Company Profile

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.